Overview: SCA5 SPTBN2 Mutation TestIntroduction: The SCA5 SPTBN2 Mutation Test detects SPTBN2 mutations to diagnose spinocerebellar ataxia, causing coordination loss. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected spinocerebellar ataxia type 5.
Other Names: SCA5 Mutation Assay, SPTBN2 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: SCA5 testing began in the 2000s with SPTBN2 gene discovery. PCR methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects SPTBN2 mutations to diagnose spinocerebellar ataxia, guides treatment, and evaluates patients with coordination loss.
Test Parameters: 1. SPTBN2 Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of coordination loss or neurological symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document coordination loss, ataxia, or family history of spinocerebellar ataxia. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, spinocerebellar ataxia implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect SPTBN2 mutations. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for SCA5 diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive SPTBN2 mutation confirms SCA5, guiding supportive therapies or genetic counseling. Negative results may require other SCA gene testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, neurological exam, or other SCA gene tests to confirm spinocerebellar ataxia diagnosis.
Test Limitations: Specific to SPTBN2; other SCA types may be missed. Clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Spinocerebellar Ataxia Guidelines, 2023; Neurology, Ikeda Y, 2022.
